שווי כולל של החברה: kalvista.com (KALV)
KalVista Pharmaceuticals (KALV) specializes in developing immunological agents while adhering to the principles of green chemistry and sustainable water management. This chart reflects an Enterprise Value of 1436.76. The company leverages its research centers in the UK and US, outsourcing the production of edema medications to third-party contractors. The primary growth driver will be the upcoming results of final trials for its hereditary angioedema therapy.
KalVista Pharmaceuticals (KALV) - פילוחי מדדים ודוחות פיננסיים
The diversification of orphan drug warehouses at KalVista Pharmaceuticals (KALV) ensures stable margins and operational resilience. These factors directly impact the calculation model that combines the company's market capitalization with its net debt. This metric determines the real business value for a potential buyer, accounting for all liabilities and liquid assets. The investor sees the actual enterprise value net of cash. By analyzing the enterprise value trend, one can assess the balance sheet recovery in advance.